Handelsavisen
prelaunch
Companies Healthcare BFRG.O
BF
BFRG.O NASDAQ Biotechnology & Life-Science Tools

Bullfrog AI Holdings Inc

$0,59
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
Op margin
-5 652,4 %
ROE
-304,2 %
Net margin
-5 569,6 %
Debt / equity
0,00
Beta
52w range
Volume
27
Day range
Prev close
$0,71
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Bullfrog AI Holdings Inc is a healthcare diagnostics company that leverages artificial intelligence to develop diagnostic tools and services for the medical research and pharmaceutical sectors.

Business. Bullfrog AI Holdings Inc (BFRG.O) is a biotechnology and life-science tools company listed on the NASDAQ. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.

Classification99 %
SectorHealth Care
Industry groupBiotechnology & Life-Science Tools
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-304,2 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning BFRG.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to BFRG.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Bullfrog AI Holdings Inc (BFRG.O) has recorded new institutional holdings, marking a notable shift in its shareholder base. As of the most recent reporting periods, three distinct investors have added positions in the company. These additions were detected on June 20, 2026, and represent the first analysis for this ticker, meaning there is no prior basis for computing delta changes against previous holdings. The largest of these new positions was established by investor ID 465, who held 157,460 shares as of December 31, 2025. This stake was valued at approximately $0.14 million, representing a portfolio weight of roughly 0.0002%. This entry provides a baseline for institutional interest in the company’s equity during the latter part of 2025. Additional accumulation occurred in the first quarter of 2026. Investor ID 499 added 17,635 shares, valued at approximately $0.03 million, as of March 31, 2026. Simultaneously, investor ID 562 acquired 15,000 shares, also valued at roughly $0.03 million, by the same March 31, 2026 date. Both of these positions carry a portfolio weight of less than 0.001%. These new holdings contribute to Bullfrog AI’s current profile, which includes four top holders. The company currently has no listed officers, analyst coverage, or index memberships. The emergence of these specific institutional positions offers the initial data points for tracking ownership concentration and investor sentiment for BFRG.O.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Bullfrog AI Holdings Inc (BFRG.O) is a biotechnology and life-science tools company listed on the NASDAQ. The firm operates within the Health Care sector, focusing on the development and sale of biotechnology products. Specific details regarding operating segments, headquarters location, and geographic revenue mix are not available in the provided data. Consequently, the company is described at the industry level as a participant in the biotechnology and life-science tools market.

    Classification99 %
    SectorHealth Care
    Industry groupBiotechnology & Life-Science Tools
    AI synthesis
    GENERATED

    Bullfrog AI has a strong liquidity position, with $2.18 million in cash and equivalents and no long-term debt, resulting in a debt-to-equity ratio of 0.0. The company's current ratio of 3.85 indicates that it has more than enough current assets to cover its current liabilities. However, the company's operating cash flow of -$5.52 million and free cash flow of -$6.49 million suggest significant cash outflows from operations.

    The company's profitability metrics are negative, with a return on equity of -304.17% and a return on assets of -231.38%. These figures are well below the industry median for biotechnology and medical research firms, indicating that Bullfrog AI is not currently generating returns for its shareholders or assets. The company's operating income of -$6.59 million and net income of -$6.49 million further underscore its unprofitable operations.

    Bullfrog AI's revenue is concentrated in a single business segment, as disclosed in its financials, with no geographic breakdown provided in the available data. The lack of geographic diversification could expose the company to regional economic or regulatory risks, though the extent of this risk is not quantified in the available data.

    The company's growth trajectory is not clearly defined in the available data, as there are no forward-looking revenue projections or historical growth rates provided. The company's current revenue of $116.67 million is not compared to prior periods, making it difficult to assess its growth performance. The absence of a clear growth narrative is a concern for investors seeking to understand the company's long-term potential.

    The risk assessment indicates that Bullfrog AI has low liquidity and dilution risk, with no immediate filing-based flags detected. The company's strong cash position and lack of long-term debt reduce the likelihood of near-term liquidity stress. However, the company's significant operating losses and negative cash flows from operations could increase the risk of future dilution if the company needs to raise additional capital. The company has not disclosed any recent equity issuances or dilution events in the available data.

    There are no recent filings or transcripts available in the provided data to assess Bullfrog AI's strategic direction or operational developments. The absence of recent disclosures limits the ability to evaluate the company's response to market conditions or its progress on key initiatives.

    Bullfrog AI Holdings Inc (BFRG.O) has recorded new institutional holdings, marking a notable shift in its shareholder base. As of the most recent reporting periods, three distinct investors have added positions in the company. These additions were detected on June 20, 2026, and represent the first analysis for this ticker, meaning there is no prior basis for computing delta changes against previous holdings. The largest of these new positions was established by investor ID 465, who held 157,460 shares as of December 31, 2025. This stake was valued at approximately $0.14 million, representing a portfolio weight of roughly 0.0002%. This entry provides a baseline for institutional interest in the company’s equity during the latter part of 2025. Additional accumulation occurred in the first quarter of 2026. Investor ID 499 added 17,635 shares, valued at approximately $0.03 million, as of March 31, 2026. Simultaneously, investor ID 562 acquired 15,000 shares, also valued at roughly $0.03 million, by the same March 31, 2026 date. Both of these positions carry a portfolio weight of less than 0.001%. These new holdings contribute to Bullfrog AI’s current profile, which includes four top holders. The company currently has no listed officers, analyst coverage, or index memberships. The emergence of these specific institutional positions offers the initial data points for tracking ownership concentration and investor sentiment for BFRG.O.

    Key takeaways
    • Bullfrog AI has a strong liquidity position with $2.18 million in cash and no long-term debt.
    • The company is unprofitable, with a return on equity of -304.17% and a return on assets of -231.38%.
    • Bullfrog AI's revenue is concentrated in a single business segment, with no geographic diversification disclosed.
    • The company has low liquidity and dilution risk, but its negative operating cash flows could increase the risk of future capital raises.
    • There are no recent filings or transcripts available to assess the company's strategic direction or operational developments.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,59
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $2.1M
    Net cash
    $2.2M
    Current ratio
    3.9
    Debt / equity
    0.0
    ROA
    -2.3%
    ROE
    -3.0%
    Cash conversion
    85.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryBiotechnology & Life-Science Tools27,7B node revenueIQV 58,8%CRL 14,5%MEDP 9,1%ALKS 5,3%PIII 5,3%ORGO 2,0%NAGE 0,5%SPRY 0,3%Other 4,2%
    Source: company disclosures · own-taxonomy revenue-covered setBFRG 0,0% · rank #72 of 78

    Business relationships

    Business relationships2 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries2
    EX21:38975e41149eEX21:38975e41149eSubsidiarie97%
    EX21:6123048454f3EX21:6123048454f3Subsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs BFRG · multiples and returns
    IQ
    IQV
    Iqvia Holdings Inc
    $181,94
    30,9B USD
    P/E
    22,7x
    vs self
    Div yield
    vs self
    ROE
    21,9 %
    +326,0 vs self
    CR
    CRL
    Charles River Laboratories
    $230,87
    11,4B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -4,6 %
    +299,6 vs self
    ME
    MEDP
    Medpace Holdings Inc
    $576,00
    16,7B USD
    P/E
    34,4x
    vs self
    Div yield
    vs self
    ROE
    75,4 %
    +379,6 vs self
    AL
    ALKS
    Alkermes PLC
    $49,53
    8,2B USD
    P/E
    39,8x
    vs self
    Div yield
    vs self
    ROE
    8,4 %
    +312,6 vs self
    PI
    PIII
    P3 Health Partners Inc
    $10,20
    73,8M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    95,3 %
    +399,5 vs self
    OR
    ORGO
    Organogenesis Holdings Inc
    $2,38
    306,2M USD
    P/E
    9,0x
    vs self
    Div yield
    vs self
    ROE
    8,5 %
    +312,7 vs self
    NA
    NAGE
    Niagen Bioscience Inc
    $3,53
    281,1M USD
    P/E
    17,4x
    vs self
    Div yield
    vs self
    ROE
    22,7 %
    +326,9 vs self
    SP
    SPRY
    Ars Pharmaceuticals Inc
    $5,51
    547,1M USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    -149,9 %
    +154,2 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-20

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-5 652,4 %Bottom quartile
    Net Margin-5 569,6 %Bottom quartile
    ROE-304,2 %Bottom quartile
    D/E0,00Above median
    Cash Conv0,85Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 242 273 sh7 grants4 insiders
    • Enright WilliamDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
    • Hanson Jason DavidDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
    • Elsey R DonDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $0,63grant · 2026-06-11
    • Hanson Jason DavidDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
    • Elsey R DonDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
    • Enright WilliamDirector · Stock Options (Right to Buy) → Common StockAcquired 15 000 @ $1,43grant · 2025-09-25
    • Singh VininderDirector, Chief Executive Officer, 10% owner · Restricted Stock Units → Common StockAcquired 152 273grant · 2025-08-22

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    • Return On Assets
      net_income / total_assets
    Source documents
    • Bullfrog AI Holdings Inc Market data — financials · 2026-05-27

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $05 insiders · last 365d
    • Blacher JoshuaChief Financial Officer · Common StockOther 4 950 · 2025-08-22
    • Hanson Jason DavidDirector · Common StockOther 5 710 · 2025-08-22
    • Hanson Jason DavidDirector · Common StockOther 2 813 · 2025-08-22
    • Singh VininderDirector, Chief Executive Officer, 10% owner · Common StockOther 75 000 · 2025-08-22
    • Enright WilliamDirector · Common StockOther 5 710 · 2025-08-22
    • Enright WilliamDirector · Common StockOther 2 813 · 2025-08-22
    • Blacher JoshuaChief Financial Officer · Common StockOther 10 050 · 2025-08-22
    • Elsey R DonDirector · Common StockOther 5 710 · 2025-08-22
    • Elsey R DonDirector · Common StockOther 2 813 · 2025-08-22

    Short positioning

    120.3Kshares short-48.1% vs prior
    1days to cover
    32.2%short of daily vol
    1.2Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    BFRG.OCanonical
    NASDAQ · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.
    Relationship graph
    BFRGEX21:389EX21:612Biotechnology
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 25.9%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): 7.1%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 1.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 8.9%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -19.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -57.0%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -49.4%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 14.3%Derived (calculated)
    • Current ratio (FY 2025-12-31): 3.85xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.31xDerived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -59.8%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 25.9%Derived (calculated)
    • Net margin (FY 2025-12-31): -5,569.6%Derived (calculated)
    • Gross margin (FY 2025-12-31): 18.8%Derived (calculated)
    • Return on equity (FY 2025-12-31): -304.2%Derived (calculated)
    • Return on assets (FY 2025-12-31): -231.4%Derived (calculated)
    • Total operating expenses (annual): USD 6.62MSEC XBRL filing
    • Cash & equivalents (annual): USD 2.18MSEC XBRL filing
    • Total assets (annual): USD 2.81MSEC XBRL filing
    • Shareholders' equity (annual): USD 2.14MSEC XBRL filing
    • Current assets (annual): USD 2.58MSEC XBRL filing
    • Total liabilities (annual): USD 672.02KSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
    • Revenue (annual): USD 116.67KSEC XBRL filing
    Showing 24 of 49 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-07-29 22:34 UTCEVENTHa Price Listing BFRG remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 71 consecutive trading days (last close $0.5699). cure deadline 2027-01-17 (172 days remaining).
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER3 institutional position changes flagged
    2026-06-15FILING8-K filing →
    2026-06-11 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-11 00:00 UTCINSIDER3 insider transactions — 2026-06 3 derivative
    2026-06-11INSIDEREnright William acquired 15.0k sh Stock Options (Right to Buy) — Director
    2026-06-11INSIDERHanson Jason David acquired 15.0k sh Stock Options (Right to Buy) — Director
    2026-06-11INSIDERElsey R Don acquired 15.0k sh Stock Options (Right to Buy) — Director
    2026-05-29FILINGS-1 filing →
    2026-05-14FILING10-Q filing →
    2026-04-30FILINGDEF 14A filing →
    2026-04-22FILING8-K filing →
    2026-04-21FILING8-K filing →
    2026-04-13FILING8-K filing →
    2026-04-01FILING424B5 filing →
    2026-04-01FILING8-K filing →
    2026-03-30FILING8-K filing →
    2026-03-19FILING10-K filing →
    2026-02-23FILING8-K filing →
    2025-09-25 00:00 UTCINSIDER3 insider transactions — 2025-09 3 derivative
    2025-09-25 00:00 UTCINSIDER3 insider transactions — 2025-09 3 derivative
    2025-09-25INSIDERElsey R Don acquired 15.0k sh Stock Options (Right to Buy) — Director
    2025-09-25INSIDERHanson Jason David acquired 15.0k sh Stock Options (Right to Buy) — Director
    2025-09-25INSIDEREnright William acquired 15.0k sh Stock Options (Right to Buy) — Director
    2025-08-22 00:00 UTCINSIDER10 insider transactions — 2025-08 1 derivative
    2025-08-22 00:00 UTCINSIDER10 insider transactions — 2025-08 1 derivative
    2025-08-22INSIDERBlacher Joshua transacted 5.0k sh — Chief Financial Officer
    2025-08-22INSIDERHanson Jason David transacted 5.7k sh — Director
    2025-08-22INSIDERHanson Jason David transacted 2.8k sh — Director
    2025-08-22INSIDERSingh Vininder transacted 75.0k sh — Director, Chief Executive Officer, 10% owner
    2025-08-22INSIDEREnright William transacted 5.7k sh — Director
    2025-08-22INSIDEREnright William transacted 2.8k sh — Director
    2025-08-22INSIDERBlacher Joshua transacted 10.1k sh — Chief Financial Officer
    2025-08-22INSIDERElsey R Don transacted 5.7k sh — Director
    2025-08-22INSIDERElsey R Don transacted 2.8k sh — Director
    Showing the 40 most recent of 43 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage